About me

Dr. Mitchell Rosen is an expert in reproductive endocrinology and fertility. He is director of the UCSF Fertility Preservation Program, which helps patients with cancer secure the ability to conceive in the future, despite the effects of aggressive cancer treatment.

Rosen earned his medical degree at Saint Louis University and completed residency training in obstetrics and gynecology at the University of Texas Medical Branch at Galveston. During his training, he was named best resident twice and received an award as best resident teacher. He completed fellowship training in reproductive endocrinology and infertility at UCSF. Also, he completed training in the UCSF embryology laboratory to qualify as a high complexity lab director.

In addition to caring for patients, Rosen teaches UCSF medical students, residents and fellows.

  • Education

    St. Louis University School of Medicine, 1998

  • Residencies

    University of Texas Medical Branch at Galveston, Obstetrics & Gynecology, 2002

  • Fellowships

    UCSF Medical Center, Reproductive Endocrinology and Infertility, 2003

  • Academic Title

    Associate Professor

Center for Reproductive Health at Mission Bay

499 Illinois St., Sixth Floor
San Francisco, CA 94158

Center for Reproductive Health at Mount Zion

2356 Sutter St., Seventh Floor
San Francisco, CA 94115

Fertility Preservation Program

499 Illinois St., Sixth Floor
San Francisco, CA 94158

My reviews

4.5

Overall Experience
87 Reviews
Dr. Rosen is great. he's one of the best doctors I've ever had.
Explained things in a way that was easy to understand
87 Reviews
Did the doctor pay attention to your concerns
87 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
79 Reviews
Knew the important information about your medical history
87 Reviews
The provider showed respect for what you had to say
86 Reviews
The provider spent enough time with me
86 Reviews
Decorative Caduceus

Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial

Recruiting

Share